Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556087 · ClinicalTrials.gov registry record · Phase 3
Distress Tolerance and Buprenorphine
A Phase 3 study, sponsored by Butler Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 59
- Enrollment target
NCT01556087: Completed Phase 3 study, sponsored by Butler Hospital.
NCT01556087 is a Phase 3 study that has completed, run by Butler Hospital. The registered enrollment target is 59 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556087, a Phase 3 study, has completed, sponsored by Butler Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 59 participants
- Enrollment target
Study Summary
The investigators propose that inability to tolerate the distress of opioid withdrawal and the negative affect associated with early abstinence are key factors in early illicit opioid lapse and subsequent buprenorphine treatment drop-out. Our intervention aimed at increasing distress tolerance is designed to increase treatment adherence.
Primary Outcome
assess patient satisfaction with services
Interventions
- BEHAVIORAL Health Education
- BEHAVIORAL Distress Tolerance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
What the finished NCT01556087 record still lists
NCT01556087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Health Education is the first listed.
NCT01556087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01556087 about?
NCT01556087 is a clinical study titled "Distress Tolerance and Buprenorphine". The investigators propose that inability to tolerate the distress of opioid withdrawal and the negative affect associated with early abstinence are key factors in early illicit opioid lapse and subsequent buprenorphine treatment drop-out. Our intervention aimed at increasing distress tolerance is de...
What is the current status of trial NCT01556087?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 59 participants. The study started on 2012-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01556087?
The interventions under investigation include: Health Education (BEHAVIORAL), Distress Tolerance (BEHAVIORAL).
Who is sponsoring clinical trial NCT01556087?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01556087's enrollment target sits among peer trials
59 1824th of 2000 higher than 176 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia